Research Article
Association of Interleukin-17F Polymorphism and Mortality Predictors with the Risk of COVID-19
Table 2
Clinical, laboratory, and radiological data of the study COVID-19 patients (n = 132).
| Variable n (%), median (25th–75th percentile) | COVID-19 patients total (n = 132) | Survivors (n = 75) | Non-survivors (n = 57) | P |
| Clinical data | Temperature (°C) | 38 (37.6–38) | 38 (37.7–38) | 38 (37.5–38.6) | 0.527 | RR (breaths/minute) | 30 (26–36) | 28 (24–30) | 35 (30–39) | <0.001 | Cough symptom score (CSS) | 2 (1–2) | 2 (1–2) | 2 (2–2) | 0.196 | Modified MRC Dyspnea Scale | 3 (3–4) | 3 (2–3) | 4 (3–4) | <0.001 |
| Clinical severity | Noncritical | 38 (28.8) | 36 (48) | 2 (3.5) | <0.001 | Critical | 94 (71.2) | 39 (52) | 55 (96.5) | Duration of hospital stay (days) | 10 (7–14) | 8 (6–13) | 11 (8–14) | 0.028 |
| Laboratory data | Hemoglobin level (g/dl) | 11.3 (10.1–12.7) | 11.3 (10.1–12.4) | 11.3 (10–13) | 0.793 | Platelet (× 103 per mm3) | 231 (176.8–282.3) | 241 (179–269) | 224 (172.5–301.5) | 0.938 | WBCs (× 103 per mm3) | 8.9 (6.4–12.9) | 7.8 (6.6–11.1) | 11.6 (8.5–16.4) | 0.022 | Lymphocyte (× 103 per mm3) | 1.1 (0.8–1.5) | 1.2 (0.85–1.5) | 1 (0.7–1.5) | 0.157 | Neutrophil (× 103 per mm3) | 6.6 (4.8–11) | 5.8 (5.2–9.8) | 8.1 (4.4–14.2) | 0.055 | CRP (mg/L) | 96 (48–142.8) | 88 (40–123) | 110 (52.5–170.5) | 0.001 | D-dimer (ng/ml) | 0.8 (0.6–1.3) | 0.7 (0.45–0.9) | 1.2 (0.85–1.5) | <0.001 |
| Radiological data | CT severity | Mild to moderate | 38 (28.8) | 37 (49.3) | 1 (1.8) | <0.001 | Severe | 94 (71.2) | 38 (50.7) | 56 (98.2) | |
| IL-17F genotype | C/T | 17 (12.9) | 11 (14.7) | 6 (10.5) | 0.482 | T/T-C/C | 115 (87.1) | 64 (85.3) | 51 (89.5) | |
|
|
CRP:C-reactive protein; CSS: cough symptom score (CSS); CT: computerized tomography MRC: modified medical research council; RR: respiratory rate, WBCs: white blood cells.
|